Two studies show that pioglitazone does not increase the risk of bladder cancer

A study published on the BMJ recently made it even more questionable whether lpyolidone increases the risk of bladder cancer. However, the two studies published at the ADA2012 Scientific Annual Meeting seem to have helped to dispel this doubt.

Pioglitazone Does Not Increase the Incidence of Bladder Cancer A study published in the morning on the morning of June 9 (US Abstract 928-P), an extended-term observational follow-up study based on the PROactive study. The results of a six-year midterm analysis show that in an observational study During the period, the incidence of any malignancy was similar between the pioglitazone group and the placebo group, and the number of cases of bladder cancer in the piloglitazone group was even smaller.

A combined analysis of PROactive's double-blind and observational follow-ups found that the same proportion of patients in both groups developed any malignancy or bladder cancer. If the use of pioglitazone was taken into account during the observation period, pioglitazone was used or never used. There was no significant difference in the risk of bladder cancer among patients who had been treated with pioglitazone.

Pioglitazone Risk of Bladder Cancer and Insulin Exhibit In addition to the PROactive extended study, the results of another retrospective cohort study (Abstract 930-P) published in the same time period in the pediment area also showed evidence of favourable pioglitazone. The study suggests that compared with insulin, pioglitazone does not increase the risk of bladder cancer, but instead reduces prostate cancer, breast cancer, lung cancer, pancreatic cancer, endometrial cancer, non-Hodgkin's lymphoma, colorectal cancer, and renal cancer. 9 cancer risks such as malignant melanoma.

The study data from the i3 InVision Data Mart database included 56 536 subjects who were newly diagnosed with type 3 diabetes using either pioglitazone or insulin as third-line therapy. The pioglitazone and insulin groups were followed for an average of 2.2 years and 1.9 years, respectively. There was no significant difference in the incidence of bladder cancer between the two groups (HR=0.92, P=0.64). With prolonged application, the risk of bladder cancer in the pioglitazone group did not increase. The total incidence of the above nine cancers in the pioglitazone group was lower than that in the insulin group (HR=0.78, P<0.0001). Regardless of the pioglitazone group or the insulin group, the total incidence of other 9 types of cancer was more than ten times higher than the incidence of bladder cancer.